Literature DB >> 17126045

Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings.

Mugdha Gore1, Ellen Dukes, David J Rowbotham, Kei-Sing Tai, Douglas Leslie.   

Abstract

Alleviating chronic pain is a global healthcare priority. Understanding the medical profile and current treatment patterns in patients with painful neuropathic disorders (PNDs) is crucial to the development of effective pain management strategies. Thus, our objective was to describe the demographic and clinical characteristics of persons with PNDs and their use of pain medications. Using the general practice research database, we categorized PNDs in two ways: Pure PNDs (which include diabetic neuropathy, postherpetic neuralgia, etc.; N=16,690) and Mixed PNDs (which include back/neck pain with neuropathic involvement; N=14,309). On average, PND patients were 55 years old (Pure, 55.4 [SD=16.9] years; Mixed, 54.3 [SD=16.4] years). Over a third had other chronic pain-related (Pure, 37.5%; Mixed, 37.1%) and nearly a quarter had non-pain related (Pure, 28.1%; Mixed, 24.1%) comorbidities. Use of medications with clinically demonstrated efficacy in PNDs was higher among patients with Pure PNDs (tricyclic antidepressants [Pure, 16.6%; Mixed, 10.1%]; 2nd generation antidepressants [Pure, 11.0%; Mixed, 9.7%]; and antiepileptics [Pure, 12.2%; Mixed, 2.6%]), whereas use of NSAIDs (Pure, 43.1%; Mixed, 65.2%) and opioids (Pure, 8.5%; Mixed, 14.3%) was higher among patients with Mixed PNDs. Average daily doses of select neuropathic pain-related medications among PND patients (Pure and Mixed) were lower than those recommended for neuropathic pain. Among both Pure and Mixed PND patients, use and doses of evidenced-based neuropathic pain-related medications was low, and lower than the use of NSAIDs (a medication class with no proven efficacy for PNDs) in each group, suggesting possible sub-optimal neuropathic pain management among these patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126045     DOI: 10.1016/j.ejpain.2006.10.004

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  24 in total

1.  Epoxy fatty acids mediate analgesia in murine diabetic neuropathy.

Authors:  K Wagner; K S S Lee; J Yang; B D Hammock
Journal:  Eur J Pain       Date:  2016-09-15       Impact factor: 3.931

2.  Painful diabetic neuropathy--new choice of first-line therapy?

Authors:  Nicholas K Tentolouris
Journal:  Nat Rev Endocrinol       Date:  2011-05-31       Impact factor: 43.330

Review 3.  Management of painful diabetic neuropathy: guideline guidance or jungle?

Authors:  Vincenza Spallone
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

4.  Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes.

Authors:  Bora Inceoglu; Karen M Wagner; Jun Yang; Ahmed Bettaieb; Nils H Schebb; Sung Hee Hwang; Christophe Morisseau; Fawaz G Haj; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

5.  Treatment of neuropathic pain with 5% lidocaine-medicated plaster: Five years of clinical experience.

Authors:  Claire Delorme; Marie L Navez; Valérie Legout; Rodrigue Deleens; Dominique Moyse
Journal:  Pain Res Manag       Date:  2011 Jul-Aug       Impact factor: 3.037

6.  Novel insights on diagnosis, cause and treatment of diabetic neuropathy: focus on painful diabetic neuropathy.

Authors:  Mitra Tavakoli; Omar Asghar; Uazman Alam; Ioannis N Petropoulos; Hassan Fadavi; Rayaz A Malik
Journal:  Ther Adv Endocrinol Metab       Date:  2010-04       Impact factor: 3.565

7.  Comparative efficacy of 3 soluble epoxide hydrolase inhibitors in rat neuropathic and inflammatory pain models.

Authors:  Karen Wagner; Bora Inceoglu; Hua Dong; Jun Yang; Sung Hee Hwang; Paul Jones; Christophe Morisseau; Bruce D Hammock
Journal:  Eur J Pharmacol       Date:  2012-12-28       Impact factor: 4.432

8.  Prevalence and characterization of neuropathic pain in a primary-care setting in Spain: a cross-sectional, multicentre, observational study.

Authors:  Concepción Pérez; María Teresa Saldaña; Ana Navarro; Inma Vilardaga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 9.  Pathophysiology and treatment of painful diabetic neuropathy.

Authors:  Mitra Tavakoli; Moaz Mojaddidi; Hassan Fadavi; Rayaz A Malik
Journal:  Curr Pain Headache Rep       Date:  2008-06

10.  Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.

Authors:  María Teresa Saldaña; Ana Navarro; Concepción Pérez; Xavier Masramón; Javier Rejas
Journal:  Rheumatol Int       Date:  2009-10-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.